Cosmo presents strong H1 2023 operational and financial results
- Reaffirmation of FY 2023 guidance of total revenues in the range of €110 million – €120 million and an operating profit in the range of €25 million – €35 million
- Repayment of €175m convertible bonds due November 2023 fully in cash at maturity
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its financial results for H1 2023, including revenues of €43.7 million (H1 2022: €41.5 million), EBITDA of €14.0 million (H1 2022: €14.9 million), an operating profit of €7.1 million (H1 2022: €8.1 million) and a profit before tax €3.7 million (H1 2022: €9.1 million).